VYNE Therapeutics has filed a patent for compositions and methods to treat skin disorders such as acne and rosacea. The patent describes a liquisoft complex composition that includes a dissolved doxycycline in a polar phase, which is homogeneously dispersed within a hydrophobic phase without the need for a surfactant. This composition aims to stabilize the active agent and improve its effectiveness in treating skin disorders. GlobalData’s report on VYNE Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on VYNE Therapeutics, nanoparticle drug conjugates was a key innovation area identified from patents. VYNE Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a liquisoft complex composition for treating skin disorders
A recently filed patent (Publication Number: US20230123488A1) describes a liquisoft complex composition that includes a polar phase containing dissolved doxycycline and a flowable or semi-solid hydrophobic phase. The polar phase is evenly dispersed within the hydrophobic phase without the need for a surfactant to stabilize the two phases. The hydrophobic phase forms an entrapment framework, with the polar phase substantially entrapped within it. The entrapment framework consists of a wax or a combination of waxes with a melting point above 37°C and a hydrophobic solvent.
The wax used in the composition can include paraffin wax, microcrystalline wax, beeswax, and hydrogenated oil. The hydrophobic solvent can be a liquid oil at 25°C, such as mineral oil, plant oil, oil rich in triglycerides, medium chain triglyceride oil, or soybean oil. The ratio of wax to polyol (a type of polyol used in the polar phase) is at least 0.5:1. The ratio of hydrophobic phase to polar phase is between 1:1 and 5:1.
The liquisoft composition can be used for the treatment of various dermatological, ophthalmological, gynecological, or mucosal diseases or disorders. It can also be used in the manufacture of medicaments for these treatments. The composition is substantially free of water, except for water associated with the active pharmaceutical agent.
The stability of doxycycline in the composition is improved compared to its stability in the polar solvent alone. When stored at 25°C for three months, the composition retains over 90% of the initial doxycycline content, with less than 0.9% breaking down to 4-epi. When stored at 5°C for six months, the composition retains over 90% of the initial doxycycline content, with less than 1.8% breaking down to 4-epi.
The liquisoft composition can be in the form of a gel or ointment and can form a foam when mixed with a liquefied or compressed gas propellant in a canister. The ratio of composition to propellant can range from about 100:4 to about 100:25.
Overall, this patent describes a novel liquisoft complex composition that allows for the stable incorporation of doxycycline and can be used for the treatment of various skin disorders involving bacterial infections and inflammation. The composition's unique structure and formulation contribute to its improved stability and potential therapeutic applications.
To know more about GlobalData’s detailed insights on VYNE Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
